This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Trojano, M Articles by Livrea, P Search for Related Content PubMed PubMed Citation Articles by Trojano, M Articles by Livrea, P Social Bookmarking                         What's this?

Soluble Intercellular Adhesion Molecule-1 (sICAM-1) in serum and cerebrospinal fluid of demyelinating diseases of the central and peripheral nervous system

Institute of Clinical Neurology, University of Bari, Policlinico Piazza G. Cesare 70124 Bari, Italy

C Avolio

Institute of Clinical Neurology, University of Bari, Policlinico Piazza G. Cesare 70124 Bari, Italy

M Ruggieri

Institute of Clinical Neurology, University of Bari, Policlinico Piazza G. Cesare 70124 Bari, Italy

F De Robertis

Institute of Clinical Neurology, University of Bari, Policlinico Piazza G. Cesare 70124 Bari, Italy

F Giuliani

Institute of Clinical Neurology, University of Bari, Policlinico Piazza G. Cesare 70124 Bari, Italy

D Paolicelli

Institute of Clinical Neurology, University of Bari, Policlinico Piazza G. Cesare 70124 Bari, Italy

P Livrea

Institute of Clinical Neurology, University of Bari, Policlinico Piazza G. Cesare 70124 Bari, Italy

Serum and cerebrospinal fluid (CSF) soluble Intercellular adhesion molecule-1 (ICAM-1) levels were evaluated (ELISA) in 22 untreated and 13 corticosteroid-treated active relapsing remitting (RR) Multiple Sclerosis (MS), in 10 untreated and 10 corticosteroid-treated Guillain-Barré syndrome (GBS) and in 17 non-inflammatory neurological diseases (NIND). Twenty-eight clinically inactive RR MS were assayed for serum sICAM-1 before and after 3 months treatment of 8 MIU rIFNb-1b taken s.c. every other day. High sICAM-1 serum levels above the NIND values were found in untreated clinically active MS and in untreated GBS (P50.05) but not in the untreated clinically inactive MS group. The active MS group showed significantly (P=0.0001) higher sICAM-1 serum levels if compared to the inactive group. Corticosteroid-treated active MS and GBS patients showed lower (P50.05) serum sICAM-1 levels than the corresponding untreated groups. Serum sICAM-1 levels after 3 months of rIFNb-1b treatment (P50.0001, paired t-test) resulted increased compared to pretreatment values in MS. The mean values of CSF/serum sICAM-1: CSF/serum Albumin ratios (sICAM-1 Index) in active untreated MS patients were higher compared to NIND (P50.005) and to corticosteroid-treated MS group (P=0.01). sICAM Index values in GBS did not differ from those in NIND. The results seem to suggest potential roles for serum sICAM-1 in downregulating the ongoing inflammatory response at the blood-brain barrier level and for CSF sICAM-1 in the maintenance of a central nervous system local immune response.

Key Words: multiple sclerosis • Guillain-Barré syndrome • soluble intercellular adhesion Molecule-1 • blood-brain barrier • blood-nerve barrier • corticosteroids • recombinant Interferon-beta-1b

Multiple Sclerosis, Vol. 4, No. 1, 39-44 (1998)
DOI: 10.1177/135245859800400110


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R.K. Zabad, L.M. Metz, T.R. Todoruk, Y. Zhang, J.R. Mitchell, M. Yeung, D.G. Patry, R.B. Bell, and V.W. Yong The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study Multiple Sclerosis, May 1, 2007; 13(4): 517 - 526. [Abstract] [PDF]

				M. Rentzos, M. Michalopoulou, C. Nikolaou, C. Cambouri, A. Rombos, A. Dimitrakopoulos, E. Kapaki, and D. Vassilopoulos Serum Levels of Soluble Intercellular Adhesion Molecule-1 and Soluble Endothelial Leukocyte Adhesion Molecule-1 in Alzheimer's Disease J Geriatr Psychiatry Neurol, December 1, 2004; 17(4): 225 - 231. [Abstract] [PDF]

				L. R. Watkins and S. F. Maier Beyond Neurons: Evidence That Immune and Glial Cells Contribute to Pathological Pain States Physiol Rev, October 1, 2002; 82(4): 981 - 1011. [Abstract] [Full Text] [PDF]

				A. Minagar, W. Jy, J. J. Jimenez, W. A. Sheremata, L. M. Mauro, W. W. Mao, L. L. Horstman, and Y. S. Ahn Elevated plasma endothelial microparticles in multiple sclerosis Neurology, May 22, 2001; 56(10): 1319 - 1324. [Abstract] [Full Text] [PDF]

				S. J. Khoury, E. J. Orav, C. R. G. Guttmann, R. Kikinis, F. A. Jolesz, and H. L. Weiner Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis Neurology, September 1, 1999; 53(4): 758 - 758. [Abstract] [Full Text] [PDF]